Truecare Biomedix

Truecare Biomedix is an Indian pharmaceutical exporter specializing in the development, manufacturing, and global supply of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2008, the company operates as a 100% Export Oriented Unit (E.O.U.) under the ownership structure of its parent company, Nuvicare LLC. Headquartered in Vadodara, Gujarat, India, Truecare Biomedix has a manufacturing facility located in Balasinor, Mahisagar, Gujarat. The company is registered with the Corporate Identification Number (CIN) U24230GJ2008PTC054019. While specific revenue figures are not publicly disclosed, the company has demonstrated a consistent export performance, with a total export value of $12.0 million USD and 436 shipments across 4 products in 2022-2026. The workforce comprises approximately 51-100 employees, reflecting a dedicated team committed to quality and innovation. For more information, the company's official website is www.tcbiomedix.com.

Truecare Biomedix operates a manufacturing facility in Balasinor, Mahisagar, Gujarat, India. This plant is fully compliant with current Good Manufacturing Practice (cGMP) standards, ensuring the production of high-quality pharmaceutical products. The facility is capable of producing a wide range of solid oral dosage forms, including tablets and capsules, with a monthly production capacity of 200 million tablets and 50 million capsules. Additionally, the plant is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating adherence to international manufacturing standards.

Specific details regarding the CEO, CFO, and other key executives of Truecare Biomedix are not publicly disclosed. However, the company's leadership emphasizes a commitment to quality and customer service, as evidenced by their mission to deliver dependable products and efficient service to customers. The management team focuses on building a system-driven organization, providing ample opportunities for employees to contribute to the company's growth and success.

Truecare Biomedix has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. Additionally, the facility operates in full compliance with the latest cGMP standards, ensuring the production of high-quality pharmaceutical products. While specific regulatory approvals in the EU, UK, Australia, and Japan are not detailed in the available sources, the company's adherence to cGMP and FDA standards suggests a commitment to meeting the regulatory requirements of these markets.

Truecare Biomedix has expanded its operations to emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. While specific details regarding WHO prequalification are not available, the company's adherence to cGMP and FDA standards suggests a commitment to meeting the regulatory requirements of these emerging markets.

Truecare Biomedix's geographic strategy demonstrates a strong focus on international markets, with a significant portion of its operations dedicated to exports. The company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. This export-centric approach suggests a strategic direction aimed at mitigating risks associated with overreliance on domestic markets and capitalizing on global demand for pharmaceutical products.

Truecare Biomedix's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. The facility has multiple FDA registrations for various products, including acetaminophen 500 mg tablets, with the most recent registration dated July 17, 2024. (fda.report) This indicates that Truecare Biomedix's products are recognized and approved for export to the United States, reflecting the company's commitment to meeting stringent regulatory standards.

Specific details regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certifications for Truecare Biomedix are not publicly available. However, the company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. Additionally, the facility operates in full compliance with the latest cGMP standards, ensuring the production of high-quality pharmaceutical products.

Truecare Biomedix's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. While specific details regarding approvals from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers are not publicly available, the company's adherence to cGMP and FDA standards suggests a commitment to meeting the regulatory requirements of Indian authorities.

Specific details regarding Form 483 observations, warning letters, or import alerts for Truecare Biomedix are not publicly available. However, the company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. Additionally, the facility operates in full compliance with the latest cGMP standards, ensuring the production of high-quality pharmaceutical products.

Truecare Biomedix operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. While specific competitors are not detailed in the available sources, the company's adherence to cGMP and FDA standards positions it favorably in the market. The company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. Additionally, the facility operates in full compliance with the latest cGMP standards, ensuring the production of high-quality pharmaceutical products.

Truecare Biomedix's key differentiators include its commitment to quality, as evidenced by its adherence to cGMP and FDA standards, and its focus on customer service, aiming to provide dependable products and efficient service to customers. The company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards.

Truecare Biomedix's strategic direction focuses on the development, manufacturing, and global supply of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. Additionally, the facility operates in full compliance with the latest cGMP standards, ensuring the production of high-quality pharmaceutical products. This strategic focus positions Truecare Biomedix to meet the growing global demand for quality pharmaceutical products.

Truecare Biomedix has demonstrated a consistent export performance, with a total export value of $12.0 million USD and 436 shipments across 4 products in 2022-2026. The company's manufacturing facility in India is registered as a 100% Export Oriented Unit (E.O.U.) and has been inspected by the US Food and Drug Administration (FDA), indicating compliance with international manufacturing standards. Additionally, the facility operates in full compliance with the latest cGMP standards, ensuring the production of high-quality pharmaceutical products.